EYPT — Eyepoint Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$4.45
-$0.13 (-2.84%)
Eyepoint Pharmaceuticals Inc (EYPT) is a biotechnology company listed on NASDAQ. It is led by Jay S. Duker M.D., based in 480 Pleasant Street, Watertown, MA, United States, 02472, with about 214 employees. EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Latest reported EYPT revenue for 2025-09-30 was $966.0K. Net income was -$164.4M. Revenue was down 81.9% from 2025-06-30 to 2025-09-30. EYPT currently screens at market cap $1.10B.
Use this EYPT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EYPT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EYPT SEC filings page. Lician reads the product cache first so this HTML stays unique to Eyepoint Pharmaceuticals Inc even when a live quote feed is slow.
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
EYPT Key Statistics
Market Cap
$1.10B
Volume
2.43M
Previous Close
$4.87
Day Range
$4.96 – $5.29
P/B Ratio
4.69
EPS
-$2.32
Revenue
$43.27M
Net Income
-$130.87M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-6.0%
Profit Margin
-302.4%
Employees
214
EYPT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $43.27M | $46.02M | $41.40M | $36.94M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$130.87M | -$70.80M | -$102.25M | -$58.42M |
| EPS (Diluted) | -$2.32 | -$1.82 | -$2.74 | -$2.03 |
Total Assets
$418.46M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$99.70M
Operating Cash Flow
-$126.23M
Free Cash Flow
$0.00
Eyepoint Pharmaceuticals Inc Company Information
- President, CEO & Director
- Jay S. Duker M.D.
- Headquarters
- 480 Pleasant Street, Watertown, MA, United States, 02472
- Website
- eyepoint.bio
- Phone
- 617 926 5000
- IPO / Founded
- 2005-01-27
- Sector
- Healthcare
- Industry
- Biotechnology